These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35234007)

  • 21. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
    Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
    EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
    Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
    Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
    Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
    N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
    Eide CA; Adrian LT; Tyner JW; Mac Partlin M; Anderson DJ; Wise SC; Smith BD; Petillo PA; Flynn DL; Deininger MW; O'Hare T; Druker BJ
    Cancer Res; 2011 May; 71(9):3189-95. PubMed ID: 21505103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
    Cortes J; Jabbour E; Kantarjian H; Yin CC; Shan J; O'Brien S; Garcia-Manero G; Giles F; Breeden M; Reeves N; Wierda WG; Jones D
    Blood; 2007 Dec; 110(12):4005-11. PubMed ID: 17785585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
    Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
    J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
    Patkar N; Ghodke K; Joshi S; Chaudhary S; Mascerhenas R; Dusseja S; Mahadik S; Gaware S; Tembhare P; Gujral S; Kabre S; Kadam-Amare P; Jain H; Dangi U; Bagal B; Khattry N; Sengar M; Arora B; Narula G; Banavali S; Menon H; Subramanian PG
    Leuk Lymphoma; 2016 Nov; 57(11):2653-60. PubMed ID: 26999421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient.
    Davulcu EA; Pekerbas M; Karaca E; Durmaz B; Özsan N; Akın H; Saydam G
    Cancer Genet; 2022 Aug; 266-267():74-80. PubMed ID: 35843036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
    Strhakova L; Bujalkova MG; Hojsikova I; Lukackova R; Behulova R; Mistrik M; Repiska V
    Neoplasma; 2011; 58(6):548-53. PubMed ID: 21895409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.